NEW YORK, Jan 9 - Ventana Medical Systems and San Diego-based Genicon Sciences signed an agreement to jointly develop Ventana’s automated microarray discovery instrument and Jenison’s RLS gene expression detection kit, then market them as an integrated genomic discovery system, the companies announced Tuesday.
The two will launch the resulting product in late 2001.The parties did not disclose the financial terms of the agreement.
The discovery system automates the process of hybridizing samples onto the array, and performs it in a high-throughput manner. The RLS technology provides a manner of detecting gene expression differences that Genicon claims is much more sensitive than current fluorescent detection technologies.
" Joining RLS Technology with the Discovery system will offer value to genomic researchers interested in procuring the most sensitive genomic microarray information on a reproducible, high-throughput system," Genicon CEO Patrick Mallon said in a statement.
“This type of alliance underscores our business model of leveraging RLS Technology to empower proprietary commercial technologies, including instrumentation, pre-spotted genomic content and other molecular tools in the genomics market, as well as broader applications in the research, drug development and clinical diagnostic markets.”Ventana and Genicon also said they plan to evaluate the sensitivity of RLS-based detection chemistry in measuring mRNA expression levels in tissues.